Efficacy of combined ethinyloestradiol (0.035 mg) and cyproterone acetate (2 mg) in acne and hirsutism in women with polycystic ovary syndrome.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Obstetrics and Gynaecology Research

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/01443619768623PMID 15511960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior.

  1995cited by this paper
• Effects of long‐term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome

  1995cited by this paper
• Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome.

  1995cited by this paper
• Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.

  1994cited by this paper
• Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.

  1994cited by this paper
• Two different pathogenetic mechanisms may play a role in acne and in hirsutism.

  1994cited by this paper
• Variable androgen sensitivity in relationship to hirsutism and acne

  1993cited by this paper
• Clinical and endocrine effects of flutamide in hyperandrogenic women.

  1993cited by this paper
• The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.

  1993cited by this paper
• Two different pathogenetic mechanisms may play a role in acne and in hirsutism

  1993cited by this paper
• Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.

  1991cited by this paper
• Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women.

  1991cited by this paper
• Hirsutism in Polycystic Ovary Syndrome: Current Concepts

  1991cited by this paper
• Monthly cyproterone acetate in the treatment of hirsute women: clinical and laboratory effects.

  1990cited by this paper
• Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycystic ovarian syndrome

  1989cited by this paper
• Time dependency and reversibility of the effects of exclusive cyproterone acetate therapy on pituitary adrenal function in hirsute women.

  1985cited by this paper
• Androgen metabolism in hirsute patients treated with cyproterone acetate.

  1984cited by this paper
• The responses of the sebaceous glands of the hypophysectomized-castrated male rat to 5 -androstanedione and 5 -androstane-3 ,17 -diol.

  1973cited by this paper
• The polycystic ovary. I. Clinical and histologic features.

  1962cited by this paper
• Clinical assessment of body hair growth in women.

  1961cited by this paper

• Management of Polycystic Ovary Syndrome in India

  2014influential citation
• Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens

  2012cites this paper
• Management of Hirsutism

  2000cites this paper